GSK-backed ViiV Healthcare has announced a significant expansion of its HIV prevention efforts, committing to triple the supply of its long-acting injectable prevention therapy in resource-limited settings. The company will make available at least 2 million doses of cabotegravir for pre-exposure prophylaxis (PrEP) at not-for-profit pricing in low- and middle-income countries during 2025 and 2026.
Strategic Global Health Initiative
The expanded access program builds upon ViiV's existing efforts to address HIV prevention in regions with high disease burden. The company, jointly owned by GSK, Pfizer, and Shionogi, has already begun implementing its not-for-profit pricing strategy in several nations. Zambia became the first recipient earlier this year, followed by rollouts in Malawi, Zimbabwe, Eswatini, and Ukraine.
The injectable cabotegravir, marketed as Apretude, represents a significant advancement in HIV prevention. Administered once every two months, the drug offers a more durable alternative to daily oral PrEP medications. Clinical testing has demonstrated its effectiveness in preventing HIV transmission, making it a valuable tool in global HIV prevention efforts.
Comprehensive Support Framework
ViiV Healthcare's commitment extends beyond drug supply. The company has established a multi-faceted approach to support HIV prevention, including:
- Fellowship programs targeting improved HIV prevention in key communities
- Grant funding for local organizations
- Formation of corporate coalitions to address HIV challenges
- A licensing agreement with the Medicines Patent Pool to facilitate generic version development
Industry-Wide Movement
This initiative reflects a broader industry trend of balancing commercial interests with global health needs. Similar efforts are being pursued by other industry leaders, including Gilead Sciences, which recently announced licensing agreements with six generic manufacturers to produce HIV medications for lower-income markets.
The expansion of ViiV's program is expected to significantly impact global HIV prevention efforts, particularly in regions where access to advanced preventive therapies has been historically limited. By the end of this year, ViiV anticipates having supplied the drug for implementation in nine additional countries, marking a substantial step forward in global HIV prevention efforts.
